Coronary restenosis: A review of mechanisms and management

American Journal of Medicine

Volumn 115, Issue 7, 2003, Pages 547-553

  Rajagopal, Vivek ^a   Rockson, Stanley G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; BETA CAROTENE; CARVEDILOL; CILAZAPRIL; CILOSTAZOL; CYANOCOBALAMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HEPARIN; HIRUDIN; HOMOCYSTEINE; LOW MOLECULAR WEIGHT HEPARIN; PACLITAXEL; PROBUCOL; PYRIDOXINE; RAPAMYCIN; STATIN; TRANILAST; TRAPIDIL;

ANEURYSM; ANGIOPLASTY; ATHERECTOMY; BRACHYTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY STENT; HUMAN; HYPERPLASIA; INTERMETHOD COMPARISON; NONHUMAN; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; THROMBOSIS;

EID: 0242329878     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(03)00477-7     Document Type: Article

References (61)

1. Bauters C., Isner J.M. The biology of restenosis. Topol E.J. Textbook of Cardiovascular Medicine. 1998;2465-2490 Lippincott-Raven, Philadelphia, Pennsylvania.
2. Glagov S., Weisenberg E., Zarins C.K., et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 316:1987;1371-1375.
3. Riessen R., Wight T.N., Pastore C., et al. Distribution of hyaluronan during extracellular matrix remodeling in human restenotic arteries and balloon-injured rat carotid arteries. Circulation. 93:1996;1141-1147.
4. Shi Y., O'Brien J.E., Fard A., et al. Adventitial myofibroblasts contribute to neointimal formation in injured porcine coronary arteries. Circulation. 94:1996;1655-1664.
5. Mintz G.S., Popma J.J., Pichard A.D., et al. Arterial remodeling after coronary angioplasty a serial intravascular ultrasound study . Circulation. 94:1996;35-43.
6. Pakala R., Willerson J.T., Benedict C.R. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation. 96:1997;2280-2286.
7. Dorn G.W. II. Role of thromboxane A2 in mitogenesis of vascular smooth muscle cells. Agents Actions Suppl. 48:1997;42-62.
8. Miano J.M., Vlasic N., Tota R.R., Stemerman M.B. Localization of Fos and Jun proteins in rat aortic smooth muscle cells after vascular injury. Am J Pathol. 142:1993;715-724.
9. Ward M.R., Tsao P.S., Agrotis A., et al. Low blood flow after angioplasty augments mechanisms of restenosis: inward vessel remodeling, cell migration, and activity of genes regulating migration. Arterioscler Thromb Vasc Biol. 21:2001;208-213.
10. Wilcox J.N., Waksman R., King S.B., Scott N.A. The role of the adventitia in the arterial response to angioplasty: the effect of intravascular radiation. Int J Radiat Oncol Biol Phys. 36:1996;789-796.
11. Pickering J.G., Ford C.M., Chow L.H. Evidence for rapid accumulation and persistently disordered architecture of fibrillar collagen in human coronary restenosis lesions. Am J Cardiol. 78:1996;633-637.
12. Tyagi S.C., Meyer L., Kumar S., et al. Induction of tissue inhibitor of metalloproteinase and its mitogenic response to endothelial cells in human atherosclerotic and restenotic lesions. Can J Cardiol. 12:1996;353-362.
13. Ribichini F., Steffenino G., Dellavalle A., et al. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme: a major risk factor and a marker of risk for coronary stent restenosis. Circulation. 97:1998;147-154.
14. Di Castelnuovo A., de Gaetano G., Donati M.B., Iacoviello L. Platelet glycoprotein receptor IIIa polymorphism PIA1/PIA2 and coronary risk: a meta-analysis. Thromb Haemost. 85:2001;626-633.
15. Ortleppg J.R., Hoffmann R., Killian A., et al. The 4G/5G promotor polymorphism of the plasminogen activator inhibitor- 1 gene and late lumen loss after coronary stent placement in smoking and nonsmoking patients. Clin Cardiol. 24:2001;585-591.
16. Roguin A., Hochberg I., Nikolsky E., et al. Haptoglobin phenotype as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 87:2001;330-332.
17. Myler R.K., Shaw R.E., Stertzer S.H., et al. Recurrence after coronary angioplasty. Cathet Cardiovasc Diagn. 13:1987;77-86.
18. Strauss B.H., Lau H.K., Bowman K.A., et al. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation1999. 100:1999;1616-1622.
19. Mizuno O., Ikeda U., Hojo Y., et al. Tissue factor expression in coronary circulation. as a prognostic factor for late restenosis after coronary angioplasty. Cardiology. 95:2001;84-89.
20. Safian R.D., McCabe C.H., Sipperly M.E., et al. Initial success and long-term follow-up of percutaneous transluminal coronary angioplasty in chronic total occlusions versus conventional stenoses. Am J Cardiol. 61:1988;23G-28G.
21. Violaris A.G., Melkert R., Herrman J.P., Serruys P.W. Role of angiographically identifiable thrombus on long-term luminal renarrowing after coronary angioplasty: a quantitative angiographic analysis. Circulation1996. 93:1996;889-897.
22. Platko W.P., Hollman J., Whitlow P.L., Franco I. Percutaneous transluminal angioplasty of saphenous vein graft stenosis: long-term follow-up. J Am Coll Cardiol. 14:1989;1645-1650.
23. Akiyama T., Moussa I., Reimers B., et al. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. J Am Coll Cardiol. 32:1998;1610-1618.
24. Dietz U., Rupprecht H.J., Ekinci O., et al. Angiographic analysis of immediate and long-term results of PTCR vs. PTCA in complex lesions (COBRA study). Catheter Cardiovasc Interv. 53:2001;359-367.
25. Appelman Y.E., Piek J.J., Strikwerda S., et al. Randomised trial of excimer laser angioplasty versus balloon angioplasty for treatment of obstructive coronary artery disease. Lancet. 347:1996;79-84.
26. Serruys P.W., de Jaegere P., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 331:1994;489-495.
27. Fischman D.L., Leon M.B., Baim D.S., et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J. Med. 331:1994;496-501.
28. Popma J.J.S.M., Lansky A.J., et al. Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation. 106:2002;1090-1096.
29. Waksman R., Raizner A.E., Yeung A.C., et al. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet. 359:2002;551-557.
30. Teirstein P.S., Massullo V., Jani S., et al. Three-year clinical and angiographic follow-up after intracoronary radiation. Circulation. 101:2000;360-365.
31. Waksman R., White R.L., Chan R.C., et al. Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation. 101:2001;2165-2171.
32. Leon M.B., Teirstein P.S., Moses J.W., et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 344:2001;250-256.
33. Morice M.-C., Serruys P.W., Sousa J.E., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 347:2002;561-566.
34. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: Drug-eluting stents: Part I. Circulation. 2003;107:2274-2279.
35. Gordon P.C., Gibson C.M., Cohen D.J., et al. Mechanisms of restenosis and redilation within coronary stents - quantitative angiographic assessment. J Am Coll Cardiol. 21:1993;1166-1174.
36. Schmidt-Ott K.M., Kagiyama S., Phillips M.I. the multiple actions of angiotensin II in atherosclerosis. Regul Pept. 93:2000;65-77.
37. Meurice T., Bauters C., Hermant X., et al. Effect of ACE inhibitors on angiographic restenosis after coronary stenting (PARIS): a randomised, double-blind, placebo-controlled trial. Lancet. 357:2001;1321-1324.
38. Takahashi S., Oida K., Fujiwara R., et al. Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture. J Cardiovasc Pharmacol. 20:1992;900-906.
39. Park S.W., Lee C.W., Kim H.S., et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 86:2000;499-503.
40. Poon M., Cohen J., Siddiqui Z., et al. Trapidil inhibits monocyte chemoattractant protein-1 and macrophage accumulation after balloon arterial injury in rabbits. Lab Invest. 79:1999;1369-1375.
41. Serruys P.W., Foley D.P., Pieper M., et al. The TRAPIST study. A multicentre randomized placebo controlled clinical trial of trapidil for prevention of restenosis after coronary stenting, measured by 3-D intravascular ultrasound. Eur Heart J. 22:2001;1938-1947.
42. Serruys P.W., Rutsch W., Heyndrickx G.R., et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. a randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention On Repeated Thromboxane-Antagonism Study (CARPORT). Circulation. 84:1991;1568-1580.
43. Voisard R., Koschnick S., Baur R., et al. High-dose diltiazem prevents migration and proliferation of vascular smooth muscle cells in various in-vitro models of human coronary restenosis. Coron Artery Dis. 8:1997;189-201.
44. Holmes D., Fitzgerald P., Goldberg S., et al. The PRESTO (Prevention of Restenosis with Tranilast and its Outcomes) protocol: a double-blind, placebo-controlled trial. Am Heart J. 139:2000;23-31.
45. Jorgensen B., Simonsen S., Endresen K., et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES). J Am Coll Cardiol. 35:2000;592-599.
46. Serruys P.W., Foley D.P., Jackson G., et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty final results of the Fluvastatin Angiographic Restenosis (FLARE) trial . Eur Heart J. 20:1999;58-69.
47. Stone N.J. The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardio (GISSI)-prevenzione trial on fish oil and vitamin E supplementation in myocardial infarction survivors. Curr Cardiol Rep. 2:2000;445-451.
48. Johansen O., Brekke M., Seljeflot I., et al. N-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. Coronary Angioplasty Restenosis Trial. J Am Coll Cardiol. 33:1999;1619-1626.
49. Serruys P.W., Foley D.P., Hofling B., et al. Carvedilol for prevention of restenosis after directional coronary atherectomy: final results of the European Carvedilol Atherectomy Restenosis (EUROCARE) trial. Circulation. 101:2000;1512-1518.
50. Tardif J.C., Cote G., Lesperance J., et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty, multivitamins and probucol study group. N Engl J Med. 337:1997;365-372.
51. Guthikonda S., Haynes W.G. Homocysteine as a novel risk factor for atherosclerosis. Curr Opin Cardiol1999. 14:1999;283-291.
52. Schnyder G., Roffi M., Pin R., et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med. 345:2001;1593-1600.
53. Gimple L.W., Herrmann H.C., Winniford M., Mammen E. Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 83:1999;1524-1529.
54. Serruys P.W., Herrman J.P., Simon R., et al. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med. 333:1995;757-763.
55. Scott N.A., Crocker I.R., Yin Q., et al. Inhibition of vascular cell growth by X-ray irradiation: comparison with gamma radiation and mechanism of action. Int J Radiat Oncol Biol Phys. 50:2001;485-493.
56. Raizner A.E., Oesterle S.N., Waksman R., et al. Inhibition of restenosis with beta-emitting radiotherapy: report of the Proliferation Reduction with Vascular Energy Trial (PREVENT). Circulation2000. 102:2000;951-958.
57. Verin V., Popowski Y., de Bruyne B., et al. Endoluminal beta-radiation therapy for the prevention of coronary restenosis after balloon angioplasty. The dose-finding study group. N Engl J Med. 344:2001;243-249.
58. Teirstein PS, Kuntz RE. New frontiers in interventional cardiology: intravascular radiation to prevent restenosis. Circulation. 2001;104:2620-2626.
59. Waksman R., Ajani A.E., White R.L., et al. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). Circulation. 103:2001;2332-2335.
60. Waksman R., Ajani A.E., Pinnow E., et al. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS . Circulation. 106:2002;776-778.
61. Park S.-J., Shim W.H., Ho D.S., et al. Apaclitaxel-eluting stent for the prevention of coronary restenosis. N Engl J Med. 348:2003;1537-1545.